We also found that the treatment with LiCl, a GSK-3β-specific inhibitor, reversed the effect of AQP3 downregulation on phospho-GSK-3β, β-catenin, and CD44 levels in GC cells. The gene discussed is AQP3; the disease is gastric cancer.